Bone quality regulator identified, suggests drug target

December 13, 2005

UCSF scientists have determined that the quality of bone matrix, a key component of bone, is regulated by a molecule known as transforming growth factor beta. The finding, they say, suggests a possible target for preventing and treating bone fractures associated with aging and genetic diseases.

The study will be reported later this week in the Online Early Edition of Proceedings of the National Academy of Sciences (PNAS).

The ability of bone to resist damage depends on the mass, or quantity, of bone, its architecture and the quality of bone matrix, the mineralized material between cells.

Several molecular factors have been shown to regulate the mass and architecture of bone. So far, however, none have been shown to regulate bone matrix, which is responsible for bone elasticity and toughness.

There has been significant disagreement about whether the quality of bone matrix varies among individuals and, if it does, whether it could be altered for therapeutic reasons. In any case, until now, scientists have lacked a strategy for measuring its quality and teasing out its impact, says senior study author Tamara Alliston, PhD, UCSF assistant adjunct professor of Cell and Tissue Biology.

In the current study, the team explored whether transforming growth factor beta (TGF-ß) regulates the properties of bone matrix because there were hints that it might. TGF-ß is known to play a role in the development of osteoblasts, cells that produce bone matrix.

The researchers carried out their evaluation in five sets of mice genetically engineered to produce differing levels of TGF-ß signaling within osteoblasts, and, for comparison, in normal, or 'wild type' mice. After the animals had been euthanized, the team utilized highly sensitive instruments developed in the materials sciences -- atomic-force microscopy, x-ray tomography and micro-Raman spectroscopy -- to measure the properties of bone matrix independent of bone mass and architecture. They also compared the bones' resistance to fracture in a bending test.

The results were notable, according to Alliston. In animals genetically engineered to produce high levels of TGF-ß, the measurements of bone matrix indicated increased susceptibility to fracture. The matrix was less elastic, less hard and contained lower levels of the mineral calcium phosphate. In addition, the animals' bones were less resistant to fracture in the bending test.

In contrast, in animals with low levels of TGF-ß the bone matrix was more elastic, harder, had higher mineral concentration and the bone overall had increased mass. In addition, the bones were more resistant to fracture in the bending test.

The bones studied included the femur, tibia and calvarial parietal bones.

"This is the first evidence that properties of bone matrix can be regulated by a growth factor and that by modifying the TGF-ß pathway, specifically, these properties can be controlled," says Alliston.

The study suggests, she says, that TGF-ß could be targeted for clinical intervention in patients. "By decreasing TGF-ß signaling at the relevant site in the body, we may be able to improve the quality of bone to either prevent the damage that occurs in osteoarthritis and osteoporosis, or improve the quality and speed of bone repair following bone fracture, joint implantation, dental implants or bone grafting.

Aging baby boomers

This strategy could prove particularly useful for aging baby boomers, as joint-replacement therapy often fails over the course of years, says Alliston. Hip replacements, for example, often fail within 15 years, and a second replacement takes a significant toll on the body. A person receiving a hip replacement at age 55 or 60 generally will require a second one by age 70.

"If we could decrease the production of TGF-ß at the site of the transplant, we might be able to strengthen the quality of bone being formed," says the lead author of the study, Guive Balooch, BA, in the UCSF Graduate Program in Oral and Craniofacial Sciences and Division of Bioengineering.

Of note, clinical trials are being developed to test whether a drug that inhibits TGF-ß will prevent cancers from metastasizing in patients, says co-senior author Rik Derynck, PhD, director of the UCSF Program in Craniofacial and Mesenchymal Biology, UCSF Department of Cell and Tissue Biology, and co-director of the UCSF Institute of Stem Cell and Tissue Biology. This separate line of investigation involving TGF-ß builds on evidence that cancer cells "up regulate" or increase, TGF-ß when they decide to metastasize. Scientists hypothesize that the increased levels of TGF-ß enhance the ability of cancer cells to invade other tissues.

Such a drug could also prove useful in modifying bone quality. It could even prove useful in treating the bone deterioration that often occurs when cancers metastasize to the bone, he says.

It is worth noting that the findings do not detract from the theory that bone mass, or quantity, is an important determinant of bones' ability to withstand fracture, says Alliston. One set of genetically engineered mice in the study had higher quality of bone matrix and lower bone mass -- and the bone fractured more easily.

The overall finding, she says, was that a reduction in TGF-ß signaling enhanced the quality of bone matrix, as well as the bone mass, collectively enabling the bone to better resist fracture.

The team is now exploring the functional significance of the bone matrix properties. "We have identified several factors we think are important, and are in the process of defining their contribution to fracture-resistance," she says.

Risk of bone fractures

Susceptibility to bone fractures and bone deterioration increases with age, often due to metabolic changes. Significant bone loss is diagnosed as osteoporosis. Deterioration in the bone and cartilage of joints is known as osteoarthritis.

Some diseases of bone degeneration are genetic, such as osteogenesis imperfecta, which is characterized by brittleness of bone, rather than loss of bone, and osteopetrosis, in which bones become overly dense, leading to a variety of significant disorders, including blindness, deafness, pathological fractures, and infections.

The new finding offers provocative hints that defects in TGF-ß signaling could play a role in some genetic diseases. Building on ongoing work in the lab, the team is now exploring strategies that could lead them toward TGF-ß's mechanism of action.
-end-
Other co-authors of the study were Mehdi Balooch, Grayson W. Marshall and Sally J. Marshall, UCSF Graduate Program in Oral and Craniofacial Sciences and UCSF Department of Preventive and Restorative Dental Sciences; Ravi K. Nalla and R.O. Ritchie, Materials Science Division, Lawrence Berkeley Laboratory, Department of Materials and Engineering, University of California, Berkeley; Stephen Schilling, Department of Pharmacology and Cancer Biology, Duke University; Ellen H. Filvaroff, Department of Molecular Oncology, Genentech Inc.

The study was funded by an Arthritis Foundation Hulda Irene Duggan Arthritis Investigator Award, the National Institutes of Health and the Department of Energy.

University of California - San Francisco

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.